keyword
MENU ▼
Read by QxMD icon Read
search

Post metastasis prostate cancer

keyword
https://www.readbyqxmd.com/read/29744471/outcomes-of-salvage-radical-prostatectomy-following-more-than-one-failed-local-therapy
#1
Arjun Sivaraman, Peter Scardino, James Eastham
Purpose: To describe the salvage radical prostatectomy (sRP) experience in patients presenting with recurrent, clinically localized prostate cancer after multiple failed local treatments. Materials and Methods: Among the 251 sRP performed during 2000-2016, 11 patients had failed multiple local therapies. We describe baseline clinical characteristics at primary cancer diagnosis and prior to sRP, surgical information, complications and oncological outcomes. Results: The mean±standard deviation age at sRP was 65±5 years and the median (interquartile range) serum prostate-specific antigen (PSA) level was 2 (1...
May 2018: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/29729848/development-and-validation-of-a-28-gene-hypoxia-related-prognostic-signature-for-localized-prostate-cancer
#2
Lingjian Yang, Darren Roberts, Mandeep Takhar, Nicholas Erho, Becky A S Bibby, Niluja Thiruthaneeswaran, Vinayak Bhandari, Wei-Chen Cheng, Syed Haider, Amy M B McCorry, Darragh McArt, Suneil Jain, Mohammed Alshalalfa, Ashley Ross, Edward Schaffer, Robert B Den, R Jeffrey Karnes, Eric Klein, Peter J Hoskin, Stephen J Freedland, Alastair D Lamb, David E Neal, Francesca M Buffa, Robert G Bristow, Paul C Boutros, Elai Davicioni, Ananya Choudhury, Catharine M L West
BACKGROUND: Hypoxia is associated with a poor prognosis in prostate cancer. This work aimed to derive and validate a hypoxia-related mRNA signature for localized prostate cancer. METHOD: Hypoxia genes were identified in vitro via RNA-sequencing and combined with in vivo gene co-expression analysis to generate a signature. The signature was independently validated in eleven prostate cancer cohorts and a bladder cancer phase III randomized trial of radiotherapy alone or with carbogen and nicotinamide (CON)...
April 23, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29721191/microrna-652-induces-ned-in-lncap-and-emt-in-pc3-prostate-cancer-cells
#3
Robert K Nam, Tania Benatar, Yutaka Amemiya, Christopher J D Wallis, Joan Miguel Romero, Melina Tsagaris, Christopher Sherman, Linda Sugar, Arun Seth
MicroRNAs (miRNAs) are small noncoding RNA molecules that post-transcriptionally regulate gene expression. Dysregulation of miRNAs is frequently associated with disease and, in particular, is involved in prostate cancer progression. Next generation miRNA sequencing identified a panel of five miRNAs associated with prostate cancer recurrence and metastasis. High expression of one of these five miRNAs, miR-652, correlated significantly with an increased rate of prostate cancer biochemical recurrence. Overexpression of miR-652 in prostate cancer cells, PC3 and LNCaP, resulted in increased growth, migration and invasion...
April 10, 2018: Oncotarget
https://www.readbyqxmd.com/read/29715200/traf4-mediated-ubiquitination-of-ngf-receptor-trka-regulates-prostate-cancer-metastasis
#4
Ramesh Singh, Dileep Karri, Hong Shen, Jiangyong Shao, Subhamoy Dasgupta, Shixia Huang, Dean P Edwards, Michael M Ittmann, Bert W O'Malley, Ping Yi
Receptor tyrosine kinases (RTKs) are important drivers of cancers. In addition to genomic alterations, aberrant activation of wild type RTKs plays an important role in driving cancer progression. However, the underlying mechanisms of how RTKs drive prostate cancer remain incompletely characterized. Here we show that non-proteolytic ubiquitination of RTK regulates its kinase activity and contributes to RTK-mediated prostate cancer metastasis. TRAF4, an E3 ubiquitin ligase, is highly expressed in metastatic prostate cancer...
May 1, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29661653/radium-223-in-the-treatment-of-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer-review-and-procedure
#5
J Orcajo-Rincon, A P Caresia-Aróztegui, M Del Puig Cózar-Santiago, J R García-Garzón, M de Arcocha-Torres, R C Delgado-Bolton, M J García-Velloso, S Alvarez-Ruiz, A M García-Vicente
Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223 Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease...
April 13, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29556484/discrimination-of-local-recurrence-after-radical-prostatectomy-value-of-diffusion-weighted-magnetic-resonance-imaging
#6
Taekmin Kwon, Jeong Kon Kim, Chanwoo Lee, Jaeyoon Jung, Hanjong Ahn, Choung-Soo Kim, Jun Hyuk Hong
Background: Multiparametric magnetic resonance is the most accurate imaging technique for prostate cancer detection, staging, localization, and aggressiveness evaluation. We assessed accuracy of diffusion-weighted imaging in local recurrence diagnosis after radical prostatectomy. Materials and methods: A retrospective study was conducted in 118 patients with findings suggestive of local recurrence in dynamic contrast-enhanced-magnetic resonance imaging. Local recurrence was defined clinically as a rising prostate-specific antigen level (biochemical recurrence) without radiographic evidence of distant metastasis over 6 months after surgery...
March 2018: Prostate International
https://www.readbyqxmd.com/read/29541557/efficacy-of-8-gy-single-fraction-palliative-radiation-therapy-in-painful-bone-metastases-a-single-institution-experience
#7
Muhammad Shuja, Ayman A Elghazaly, Asif Iqbal, Reham Mohamed, Amal Marie, Mutahir A Tunio, Moamen M Aly, Ali Balbaid, Mushabbab Asiri
Introduction Bone metastasis (BM) is a major complication of many solid tumors like breast, prostate, lung and renal cancers. BM leads to serious sequelae of pain, fractures, spinal cord compression and hypercalcemia. Radiotherapy has an established role in relieving pain caused by BM. Worldwide different radiotherapy schedules are being used for BM. The aim of this study is to determine the efficacy of single fraction palliative radiotherapy for painful bone metastases. Methods Between April 2014 and April 2017, single fraction radiotherapy was used to treat 73 patients in our institution...
January 8, 2018: Curēus
https://www.readbyqxmd.com/read/29506516/mir-221-5p-enhances-cell-proliferation-and-metastasis-through-post-transcriptional-regulation-of-socs1-in-human-prostate-cancer
#8
Ning Shao, Gui Ma, Jinying Zhang, Wei Zhu
BACKGROUND: To investigate the effect of miR-221-5p on cell proliferaton and metastasis of human prostate cancer in vitro and vivo. METHODS: We established PC3 cell lines with stable overexpression or silencing of miRNA-221-5p via lentivirus infection. miRNA-221-5p and its target gene SOCS1 expression levels in the stable cells were analyzed by real-time polymerase chain reaction (RT-PCR) and western blotting. Using luciferase reporter assays to study the relationship between miR-221-5p and SOCS1...
March 5, 2018: BMC Urology
https://www.readbyqxmd.com/read/29504694/glyoxalase-1-sustains-the-metastatic-phenotype-of-prostate-cancer-cells-via-emt-control
#9
Cinzia Antognelli, Rodolfo Cecchetti, Francesca Riuzzi, Matthew J Peirce, Vincenzo N Talesa
Metastasis is the primary cause of death in prostate cancer (PCa) patients. Effective therapeutic intervention in metastatic PCa is undermined by our poor understanding of its molecular aetiology. Defining the mechanisms underlying PCa metastasis may lead to insights into how to decrease morbidity and mortality in this disease. Glyoxalase 1 (Glo1) is the detoxification enzyme of methylglyoxal (MG), a potent precursor of advanced glycation end products (AGEs). Hydroimidazolone (MG-H1) and argpyrimidine (AP) are AGEs originating from MG-mediated post-translational modification of proteins at arginine residues...
May 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29475737/burden-of-metastatic-castrate-naive-prostate-cancer-patients-to-identify-men-more-likely-to-benefit-from-early-docetaxel-further-analyses-of-chaarted-and-getug-afu15-studies
#10
Gwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, Glenn Liu, Karim Fizazi, Michael A Carducci, Stephane Oudard, Florence Joly, David M Jarrard, Michel Soulie, Mario J Eisenberger, Muriel Habibian, Robert Dreicer, Jorge A Garcia, Maha H M Hussain, Manish Kohli, Nicholas J Vogelzang, Joel Picus, Robert DiPaola, Christopher Sweeney
BACKGROUND: Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether patients with low-volume (LV) disease benefit from early D. OBJECTIVE: To define the overall survival (OS) of aggregate data of patient subgroups from the CHAARTED and GETUG-AFU15 studies, defined by metastatic burden (HV and LV) and time of metastasis occurrence (at diagnosis or after prior local treatment [PRLT])...
February 20, 2018: European Urology
https://www.readbyqxmd.com/read/29416746/mir-518f-5p-decreases-tetraspanin-cd9-protein-levels-and-differentially-affects-non-tumourigenic-prostate-and-prostate-cancer-cell-migration-and-adhesion
#11
Danielle R Bond, Crystal Naudin, Adam P Carroll, Belinda J Goldie, Joshua S Brzozowski, Helen M Jankowski, Murray J Cairns, Leonie K Ashman, Christopher J Scarlett, Judith Weidenhofer
Tetraspanin CD9 is generally considered to be a metastasis suppressor, with decreased levels associated with progression and metastasis in many advanced stage cancers. Little is known about the cause of CD9 dysregulation in prostate cancer, however there are several miRNA-binding sites in the 3´UTR of the transcript suggesting it could be post-transcriptionally regulated. Using microarrays and luciferase assays in tumourigenic and non-tumourigenic prostate cell lines we identified miR-518f-5p as a regulator of the CD9 3'UTR gene expression, and decreased expression of endogenous CD9 in non-tumorigenic prostate RWPE1 and prostate cancer DU145 cells...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29383293/a-pilot-study-in-the-use-of-activity-trackers-for-assessing-response-to-palliative-radiotherapy
#12
Valérie Dorion, Louise Lambert, Alexandra Frazzi, Jean-François Cayer, Philip Wong
Purpose Radiation therapy (RT) has been a frequently used treatment for painful bone metastasis. The aim of this study was to determine the feasibility of using activity trackers (AT) to assess the patient prognosis and the effects of palliative RT. Methods and materials Twelve patients planned to receive palliative RT for axial metastases and were prospectively recruited to participate in this pilot clinical trial. The patients were eligible if there was no intent to change the analgesic medications prior to or within seven days of palliative RT...
November 22, 2017: Curēus
https://www.readbyqxmd.com/read/29374406/minimum-residual-disease-in-patients-post-radical-prostatectomy-for-prostate-cancer-theoretical-considerations-clinical-implications-and-treatment-outcome
#13
Nigel P Murray, Socrates Aedo, Cynthia Fuentealba, Eduardo Reyes, Anibal Salazar
Introduction: Minimal residual disease (MRD) remaining after curative therapy for prostate cancer has the potential for growth and can result in metastasis. Circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) could represent different types of MRD. We here determined; biochemical failure free survival rates; time to BF after 10 years follow-up; and the presence of CPCs and mM in patients treated with radical prostatectomy (RP) for prostate cancer. Methods and Patients: One month after RP, blood and bone marrow were sampled for assessment of CPCs and mM...
January 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29341215/microrna181c-inhibits-prostate-cancer-cell-growth-and-invasion-by-targeting-multiple-erk-signaling-pathway-components
#14
Zhengzheng Su, Mengni Zhang, Miao Xu, Xinglan Li, Junya Tan, Yunyi Xu, Xiuyi Pan, Ni Chen, Xueqin Chen, Qiao Zhou
BACKGROUND: The ERK signaling pathway is frequently deregulated in tumorigenesis, mostly by classical mechanisms such as gene mutation of its components (eg, RAS and RAF). However, whether and how multiple key components of ERK pathway are regulated by microRNAs are not clear. METHODS: We firstly predicted post-transcriptional regulation of multiple key components of the ERK signaling pathway by miR181c through bioinformatics analysis, and then confirmed the post-transcriptional regulation by dual luciferase reporter gene assays and Western blot analysis...
January 16, 2018: Prostate
https://www.readbyqxmd.com/read/29301501/inhibition-of-neddylation-facilitates-cell-migration-through-enhanced-phosphorylation-of-caveolin-1-in-pc3-and-u373mg-cells
#15
Sung Yeon Park, Jong-Wan Park, Gun-Woo Lee, Lan Li, Yang-Sook Chun
BACKGROUND: Protein neddylation is a post-translational modification by a covalent conjugation with the neural precursor cell expressed, developmentally downregulated 8 (NEDD8). Although this process has been reported to participate in diverse cellular signaling, little is known about its role in cancer cell migration. Given a recent proteomics report showing that NEDD8 is downregulated in prostate cancer tissues versus normal prostate tissues, we tested the possibility that neddylation plays a role in cancer evolution, and then tried to identify target proteins of the neddylation...
January 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29288003/tertiary-gleason-pattern-in-radical-prostatectomy-specimens-is-associated-with-worse-outcomes-than-the-next-higher-gleason-score-group-in-localized-prostate-cancer
#16
Mehmet Özsoy, David D'Andrea, Marco Moschini, Beat Foerster, Mohammad Abufaraj, Romain Mathieu, Alberto Briganti, Pierre I Karakiewicz, Morgan Roupret, Christian Seitz, Anna Katarzyna Czech, Martin Susani, Shahrokh F Shariat
AIM: To assess the predictive value of TGP on biochemical recurrence (BCR) and its association with clinicopathological outcomes in a large, multicenter cohort of patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP). MATERIALS AND METHODS: Records of 6,041 patients who were treated with RP between 2000 and 2011 for clinically nonmetastatic PCa were, retrospectively, analyzed from prospectively collected datasets. BCR-free survival rates were assessed using univariable and multivariable cox-regression analyses...
December 26, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29284672/hospice-admission-and-survival-after-18-f-fluoride-pet-performed-for-evaluation-of-osseous-metastatic-disease-in-the-national-oncologic-pet-registry
#17
Ilana F Gareen, Bruce E Hillner, Lucy Hanna, Rajesh Makineni, Fenghai Duan, Anthony F Shields, Rathan M Subramaniam, Barry A Siegel
We have previously reported that PET using18 F-fluoride (NaF PET) for assessment of osseous metastatic disease was associated with substantial changes in intended management in Medicare beneficiaries participating in the National Oncologic PET Registry (NOPR). Here, we use Medicare administrative data to examine the association between NaF PET results and hospice claims within 180 d and 1-y survival. Methods: We classified NOPR NaF PET results linked to Medicare claims by imaging indication (initial staging [IS]; detection of suspected first osseous metastasis [FOM]; suspected progression of osseous metastasis [POM]; or treatment monitoring [TM]) and type of cancer (prostate, lung, breast, or other)...
March 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29233664/performance-of-a-prostate-cancer-genomic-classifier-in-predicting-metastasis-in-men-with-prostate-specific-antigen-persistence-postprostatectomy
#18
Daniel E Spratt, Darlene L Y Dai, Robert B Den, Patricia Troncoso, Kasra Yousefi, Ashley E Ross, Edward M Schaeffer, Zaid Haddad, Elai Davicioni, Rohit Mehra, Todd M Morgan, Walter Rayford, Firas Abdollah, Edouard Trabulsi, Mary Achim, Elsa Li Ning Tapia, Mireya Guerrero, Robert Jeffrey Karnes, Adam P Dicker, Mark A Hurwitz, Paul L Nguyen, Felix F Y Feng, Stephen J Freedland, John W Davis
BACKGROUND: Prostate cancer patients who have a detectable prostate-specific antigen (PSA) postprostatectomy may harbor pre-existing metastatic disease. To our knowledge, none of the commercially available genomic biomarkers have been investigated in such men. OBJECTIVE: To evaluate if a 22-gene genomic classifier can independently predict development of metastasis in men with PSA persistence postoperatively. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional study of 477 men who underwent radical prostatectomy (RP) between 1990 and 2015 from three academic centers...
December 10, 2017: European Urology
https://www.readbyqxmd.com/read/29223469/oncological-and-functional-outcomes-of-elderly-men-treated-with-hifu-vs-minimally-invasive-radical-prostatectomy-a-propensity-score-analysis
#19
Paolo Capogrosso, Eric Barret, Rafael Sanchez-Salas, Igor Nunes-Silva, François Rozet, Marc Galiano, Eugenio Ventimiglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi, Xavier Cathelineau
AIM: To assess outcomes of whole gland high-intensity focused ultrasound (HIFU) as compared with minimally-invasive radical prostatectomy (MIRP) in elderly patients. MATERIALS & METHODS: Patients aged ≥70 years with, cT1-cT2 disease, biopsy Gleason score (GS) 3 + 3 or 3 + 4 and preoperative PSA ≤10 ng/mL were submitted to either whole-gland HIFU or MIRP. Propensity-score matching analysis was performed to ensure the baseline equivalence of groups. Follow-up visits were routinely performed assessing PSA and urinary function according to the International Continence Score (ICS) and the International Prostatic Symptoms Score (IPSS) questionnaires...
January 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29212233/lncrna-xist-acts-as-a-tumor-suppressor-in-prostate-cancer-through-sponging-mir-23a-to-modulate-rkip-expression
#20
Yang Du, Xiao-Dong Weng, Lei Wang, Xiu-Heng Liu, Heng-Cheng Zhu, Jia Guo, Jin-Zhuo Ning, Cheng-Cheng Xiao
Accumulating evidences have indicated that aberrant expression of long non-coding RNAs (LncRNAs) is tightly associated with cancer development. Previous studies have reported that lncRNA XIST regulates tumor malignancies in several cancers. However, the underlying mechanism of XIST in prostate cancer remains unclear. In the current study, we found that XIST was down-regulated in prostate cancer specimens and cell lines. Low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients...
November 7, 2017: Oncotarget
keyword
keyword
76410
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"